home
Author : admin

JAMA announces Rivoceranib's NSCLC combination therapy

The results of the combination therapy with Rivoceranib (Apatinib) and Vinorelbine in patients with wild-type Non-Small Cell Lung Cancer (NSCLC) without standard therapy were published in a paper published in the JAMA Network Open of the Journal of the American Medical Association (JAMA).


 


In Phase 2 clinical trials conducted by Central South University in China, the disease control rate (DCR) was 76.7%, the overall response rate (ORR) was 36.7%, the median Progression-Free Survival (mPFS) was 4.5 months, and the median Overall Survival (mOS) was 10 months and the major indicators had a meaningful effect.


 


The article mentioned that the combination treatment of Apatinib and Vinorelbine could be "a very promising treatment" because it was effective as a third-line treatment in NSCLC patients without the genetic mutation, and its toxicity was manageable.


 


An HLB official said, “The treatment of lung cancer is subdivided according to biomarkers such as EGFR, ALK, ROS1, and PD-L1, and the strength of Rivoceranib as a drug that can be used as the basis for combination therapy with various target drugs has been confirmed once again. ”